FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2539165044> ?p ?o ?g. }

• W2539165044 endingPage "373" @default.
• W2539165044 startingPage "363" @default.
• W2539165044 abstract "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of azacitidine (Celgene) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of acute myeloid leukaemia with more than 30 % bone marrow blasts in adults who are not eligible for haematopoietic stem cell transplantation, as part of the NICE’s Single Technology Appraisal process. The Peninsula Technology Assessment Group was commissioned to act as the Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company’s submission to NICE. The clinical effectiveness data used in the company’s economic analysis were derived from a single randomised controlled trial, AZA-AML-001. It was an international, multicentre, controlled, phase III study with an open-label, parallel-group design conducted to determine the efficacy and safety of azacitidine against a conventional care regimen (CCR). The CCR was a composite comparator of acute myeloid leukaemia treatments currently available in the National Health Service: intensive chemotherapy followed by best supportive care (BSC) upon disease relapse or progression, non-intensive chemotherapy followed by BSC and BSC only. In AZA-AML-001, the primary endpoint was overall survival. Azacitidine appeared to be superior to the CCR, with median overall survival of 10.4 and 6.5 months, respectively. However, in the intention-to-treat analysis, the survival advantage associated with azacitidine was not statistically significant. The company submitted a de novo economic evaluation based on a partitioned survival model with four health states: “Remission”, “Non-remission”, “Relapse/Progressive disease” and “Death”. The model time horizon was 10 years. The perspective was the National Health Service and Personal Social Services. Costs and health effects were discounted at the rate of 3.5 % per year. The base-case incremental cost-effectiveness ratio (ICER) of azacitidine compared with the CCR was £20,648 per quality-adjusted life-year (QALY) gained. In the probabilistic sensitivity analysis, the mean ICER was £17,423 per QALY. At the willingness-to-pay of £20,000, £30,000 and £50,000 per QALY, the probability of azacitidine being cost effective was 0.699, 0.908 and 0.996, respectively. The ERG identified a number of errors in Celgene’s model and concluded that the results of the company’s economic evaluation could not be considered robust. After amendments to Celgene’s model, the base-case ICER was £273,308 per QALY gained. In the probabilistic sensitivity analysis, the mean ICER was £277,123 per QALY. At a willingness-to-pay of £100,000 per QALY, the probability of azacitidine being cost effective was less than 5 %. In all exploratory analyses conducted by the ERG, the ICER exceeded the NICE’s cost-effectiveness threshold range of £20,000–30,000 per QALY. Given the evidence provided in the submission, azacitidine did not fulfil NICE’s end-of-life criteria. After considering the analyses performed by the ERG and submissions from clinician and patient experts, the NICE Appraisal Committee did not recommend azacitidine for this indication." @default.
• W2539165044 created "2016-10-28" @default.
• W2539165044 creator A5027344461 @default.
• W2539165044 creator A5037428320 @default.
• W2539165044 creator A5047943091 @default.
• W2539165044 creator A5049525257 @default.
• W2539165044 creator A5054440572 @default.
• W2539165044 creator A5065378097 @default.
• W2539165044 creator A5082727271 @default.
• W2539165044 date "2016-10-17" @default.
• W2539165044 modified "2023-10-17" @default.
• W2539165044 title "Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal" @default.
• W2539165044 cites W1600365609 @default.
• W2539165044 cites W1987359936 @default.
• W2539165044 cites W1988174589 @default.
• W2539165044 cites W2043549803 @default.
• W2539165044 cites W2070320826 @default.
• W2539165044 cites W2071066672 @default.
• W2539165044 cites W2102423175 @default.
• W2539165044 cites W2114441791 @default.
• W2539165044 cites W2116858301 @default.
• W2539165044 cites W2142938360 @default.
• W2539165044 cites W2167571044 @default.
• W2539165044 cites W2170075800 @default.
• W2539165044 cites W2172277773 @default.
• W2539165044 doi "https://doi.org/10.1007/s40273-016-0453-5" @default.
• W2539165044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27752999" @default.
• W2539165044 hasPublicationYear "2016" @default.
• W2539165044 type Work @default.
• W2539165044 sameAs 2539165044 @default.
• W2539165044 citedByCount "5" @default.
• W2539165044 countsByYear W25391650442017 @default.
• W2539165044 countsByYear W25391650442018 @default.
• W2539165044 countsByYear W25391650442020 @default.
• W2539165044 countsByYear W25391650442023 @default.
• W2539165044 crossrefType "journal-article" @default.
• W2539165044 hasAuthorship W2539165044A5027344461 @default.
• W2539165044 hasAuthorship W2539165044A5037428320 @default.
• W2539165044 hasAuthorship W2539165044A5047943091 @default.
• W2539165044 hasAuthorship W2539165044A5049525257 @default.
• W2539165044 hasAuthorship W2539165044A5054440572 @default.
• W2539165044 hasAuthorship W2539165044A5065378097 @default.
• W2539165044 hasAuthorship W2539165044A5082727271 @default.
• W2539165044 hasBestOaLocation W25391650442 @default.
• W2539165044 hasConcept C104317684 @default.
• W2539165044 hasConcept C112930515 @default.
• W2539165044 hasConcept C126322002 @default.
• W2539165044 hasConcept C138816342 @default.
• W2539165044 hasConcept C150194340 @default.
• W2539165044 hasConcept C159110408 @default.
• W2539165044 hasConcept C185592680 @default.
• W2539165044 hasConcept C190727270 @default.
• W2539165044 hasConcept C199360897 @default.
• W2539165044 hasConcept C203092338 @default.
• W2539165044 hasConcept C2776239401 @default.
• W2539165044 hasConcept C2779256446 @default.
• W2539165044 hasConcept C3019080777 @default.
• W2539165044 hasConcept C41008148 @default.
• W2539165044 hasConcept C524218345 @default.
• W2539165044 hasConcept C535046627 @default.
• W2539165044 hasConcept C55493867 @default.
• W2539165044 hasConcept C71924100 @default.
• W2539165044 hasConceptScore W2539165044C104317684 @default.
• W2539165044 hasConceptScore W2539165044C112930515 @default.
• W2539165044 hasConceptScore W2539165044C126322002 @default.
• W2539165044 hasConceptScore W2539165044C138816342 @default.
• W2539165044 hasConceptScore W2539165044C150194340 @default.
• W2539165044 hasConceptScore W2539165044C159110408 @default.
• W2539165044 hasConceptScore W2539165044C185592680 @default.
• W2539165044 hasConceptScore W2539165044C190727270 @default.
• W2539165044 hasConceptScore W2539165044C199360897 @default.
• W2539165044 hasConceptScore W2539165044C203092338 @default.
• W2539165044 hasConceptScore W2539165044C2776239401 @default.
• W2539165044 hasConceptScore W2539165044C2779256446 @default.
• W2539165044 hasConceptScore W2539165044C3019080777 @default.
• W2539165044 hasConceptScore W2539165044C41008148 @default.
• W2539165044 hasConceptScore W2539165044C524218345 @default.
• W2539165044 hasConceptScore W2539165044C535046627 @default.
• W2539165044 hasConceptScore W2539165044C55493867 @default.
• W2539165044 hasConceptScore W2539165044C71924100 @default.
• W2539165044 hasIssue "3" @default.
• W2539165044 hasLocation W25391650441 @default.
• W2539165044 hasLocation W25391650442 @default.
• W2539165044 hasLocation W25391650443 @default.
• W2539165044 hasLocation W25391650444 @default.
• W2539165044 hasLocation W25391650445 @default.
• W2539165044 hasOpenAccess W2539165044 @default.
• W2539165044 hasPrimaryLocation W25391650441 @default.
• W2539165044 hasRelatedWork W1803511184 @default.
• W2539165044 hasRelatedWork W1974629898 @default.
• W2539165044 hasRelatedWork W2020460752 @default.
• W2539165044 hasRelatedWork W2040293510 @default.
• W2539165044 hasRelatedWork W2070359354 @default.
• W2539165044 hasRelatedWork W2091656459 @default.
• W2539165044 hasRelatedWork W2411005310 @default.
• W2539165044 hasRelatedWork W2754292714 @default.
• W2539165044 hasRelatedWork W4205515051 @default.
• W2539165044 hasRelatedWork W4243357718 @default.

• next